NSE: TATVA | BSE: 543321 | ASM

Strong Performer, Getting Expensive

Download real time

1940.60 99.30 (5.39%)

New 52W High in past week

113.7K NSE+BSE Volume

NSE 14 Oct, 2026 3:31 PM (IST)

4,539.5

Market Cap

High in industry

Beta 1Year

Very High Volatility

Board Meeting

The next board meeting for Tatva Chintan Pharma is on 19 Oct 2026 for the purpose of Quarterly Results See details

Tatva Chintan Pharma Chem Ltd. share price target and research reports

Latest analyst research reports with target prices and PDF download for TATVA, BSE:543321 Tatva Chintan Pharma Chem Ltd.

Search Inside the pdf :

Tatva Chintan Pharma Chem Ltd.

20 Jul 2026

1940.60

5.39%

Long-Term Growth Visibility Through Capacity Expansion and Strong product growth

Accumulate: Tatva Chintan Pharma Chem ...

Target

Deven Choksey

Management remains confident of sustaining its long-term growth trajectory and does not foresee any structural issues across the value chain despite the current macro environment.

Tatva Chintan Pharma has gained 76.56% in the last 1 Year

Tatva Chintan Pharma Chem Ltd.

19 Jul 2026

1940.60

5.39%

A good start to FY27; provides confidence to achieve guidance

Buy: Tatva Chintan Pharma Chem ...

ICICI Securities Limited

Tatva Chintan Pharma Chem (TATVA)’s Q1FY27 print showed sustained EBITDA improvement (14.8% QoQ/86.4% YoY) to INR 323mn. Revenue grew 42.9% YoY, largely led by volumes, and price pass-through could show up in coming quarters.

Tatva Chintan Pharma.. has an average target of 1860.00 from 2 brokers.

Tatva Chintan Pharma Chem Ltd.

14 Jul 2026, 12:00AM

1940.60

5.39%

Tatva Chintan Pharma Chem Ltd– Q1FY27 Preview:

Accumulate: Tatva Chintan Pharma Chem ...

Target

Deven Choksey

We expect the company to grow its Revenue/EBITDA/PAT at a CAGR of 25% / 46.9% / 57.5% for the period of FY26-FY28E. The company is currently trading at 31x FY28E and we value the company at a PE of 33x FY28E EPS, implying a target price of INR 1,471 with the upside of 6.6%.

Tatva Chintan Pharma has gained 20.63% in the last 1 Month

Tatva Chintan Pharma Chem Ltd.

20 May 2026

1940.60

5.39%

Long-Term Growth Visibility Through Capacity Expansion and Product Diversification

Accumulate: Tatva Chintan Pharma Chem ...

Recommendation Target

Deven Choksey

We expect the company to grow its Revenue/EBITDA/PAT at a CAGR of 25% / 46.9% / 57.5% for the period of FY26-FY28E. The company is currently trading at 28x FY28E and we value the company at a PE of 32x FY28E EPS, implying a target price of INR 1,426 with the upside of 12.2%.

Tatva Chintan Pharma has gained 20.63% in the last 1 Month

Tatva Chintan Pharma Chem Ltd.

22 Jan 2026

1940.60

5.39%

Sustains improving revenue and profitability trajectory

Buy: Tatva Chintan Pharma Chem ...

Target

ICICI Securities Limited

Tatva Chintan Pharma Chem’s (TATVA) Q3FY26 print showed further signs of recovery, particularly in two key segments – SDA and PASC. Revenue in SDA grew 132% YoY driven by volumes while prices were stable.

Tatva Chintan Pharma has gained 20.63% in the last 1 Month

Tatva Chintan Pharma Chem Ltd.

24 Nov 2025

1940.60

5.39%

A strong quarter with recovery in SDA segment

Sell: Tatva Chintan Pharma Chem ...

Target

Deven Choksey

Tatva Chintan is transitioning into a stronger growth phase primarily driven by SDA recovery, clearer electrolyte-salt commercialization, scalable agro/pharma pipelines, and a structurally high-entry-barrier semiconductor opportunity.

Tatva Chintan Pharma Chem Ltd. is trading above all available SMAs

Tatva Chintan Pharma Chem Ltd.

03 Sep 2025

1940.60

5.39%

Improving visibility and execution warrant upgrade amid stable demand outlook

Sell: Tatva Chintan Pharma Chem ...

Deven Choksey

We expect the company to sustain robust growth over FY27E, led by stronger volume offtake in SDA segment driven by Euro-7 demand, scale-up of agro and pharma intermediates, and increasing contribution from electrolyte salts.

Tatva Chintan Pharma Chem Ltd. is trading above all available SMAs

Tatva Chintan Pharma Chem Ltd.

06 May 2025

1940.60

5.39%

TATVA remain hopeful for strong recovery in FY26

Buy: Tatva Chintan Pharma Chem ...

Target

ICICI Securities Limited

Tatva Chintan Pharma Chem’s (TATVA) performance showed signs of improvement in Q4FY25 on the revenue front, but lower gross profit marred profit recovery. TATVA is hopeful of a sharp recovery in FY26, as new products commercialise in PASC and SDA volume recovers.

Tatva Chintan Pharma has gained 76.56% in the last 1 Year

Tatva Chintan Pharma Chem Ltd.

25 Jul 2024

1940.60

5.39%

Margins impacted by high-cost inventory

Buy: Tatva Chintan Pharma Chem ...

Target

ICICI Securities Limited

Tatva Chintan Pharma Chem’s (TATVA) revenue grew 7.3% QoQ, but gross profit margin collapsed to just 45.9% (vs 57.8% in Q4FY24) due to high-cost inventory, particularly in SDA, where it had to take 15-20% price.

Tatva Chintan Pharma.. has an average target of 1860.00 from 2 brokers.

Tatva Chintan Pharma Chem Ltd.

27 Sep 2023

1940.60

5.39%

Core business normalising; new products pipeline maturing

Buy: Tatva Chintan Pharma Chem ...

Target

ICICI Securities Limited

In FY23, Tatva Chintan (TATVA) earnings were hurt from a downcycle in its SDA business, which should resume growing FY24 onwards. The addition of a significant new customer to its SDA has the potential to propel growth in the near future. PASC segment will likely reap the benefit of products under qualification and long-term growth on the back of a robust pipeline and cleaner chemistry positioning.

Tatva Chintan Pharma has gained 39.47% in the last 3 Months

VOTE: Is Tatva Chintan Pharma Chem Ltd. worth buying?

57 Votes:

Buy 59.65%

Sell 22.81%

Hold 17.54%

RESEARCH REPORTS

Accumulate SEE REPORTS >

pdf

Buy SEE REPORTS >

pdf